Lilly and Incyte provide update on supplemental NDA for baricitinib for the treatment of moderate to severe atopic dermatitis
Eli Lilly and Company and Incyte announced that the FDA will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application… read more.